The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test
- PMID: 28392973
- PMCID: PMC5367501
- DOI: 10.1097/XCE.0000000000000073
The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test
Abstract
Background: Serum YKL-40 is an inflammatory biomarker associated with disease activity and mortality in diseases characterized by inflammation such as coronary artery disease (CAD). Exercise has a positive effect on CAD, possibly mediated by a decreased inflammatory activity. This study aimed to compare serial measurements of serum YKL-40 before and after exercise in patients with stable CAD versus controls.
Materials and methods: Eleven patients with stable CAD verified by coronary angiography (>70% stenosis) and 11 patients with a computer tomography angiography with no stenosis or calcification (calcium score=0) (controls) performed a standard clinical maximal exercise test. Serum YKL-40 was measured before exercise, immediately after exercise, and every hour for 6 h.
Results: Cardiovascular risk factors were more prevalent among the CAD patients compared with the controls. CAD patients had higher serum concentration of YKL-40 at baseline compared with controls, median (interquartile range) 94 (52-151) versus 57 (45-79) μg/l. Serum YKL-40 decreased stepwise after exercise, with a median decrease of 16 (13-39) μg/l for the CAD patients and 13 (10-22) μg/l for the controls from baseline to the lowest value. Thereafter, values increased again toward baseline level. Time after exercise was a significant factor for decrease in serum YKL-40 (P<0.0001), but no difference in YKL-40 decrease over time could be demonstrated between the groups (P=0.12).
Conclusion: Serum YKL-40 is elevated in patients with documented CAD compared with controls, and it decreases stepwise after exercise in both groups, indicating an anti-inflammatory effect of exercise independent of the presence of coronary atherosclerosis.
Keywords: biomarkers; coronary artery disease; exercise test; inflammation; serum YKL-40; stable angina pectoris.
Figures



Similar articles
-
Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease.Scand J Clin Lab Invest. 2011 Sep;71(5):439-47. doi: 10.3109/00365513.2011.586470. Scand J Clin Lab Invest. 2011. PMID: 21827355
-
Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.Immunobiology. 2013 Jul;218(7):945-51. doi: 10.1016/j.imbio.2012.10.015. Epub 2012 Nov 7. Immunobiology. 2013. PMID: 23294528 Clinical Trial.
-
Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease.Atherosclerosis. 2010 Jun;210(2):590-5. doi: 10.1016/j.atherosclerosis.2009.12.016. Epub 2009 Dec 21. Atherosclerosis. 2010. PMID: 20056225
-
High serum YKL-40 level positively correlates with coronary artery disease.Biomark Med. 2017 Feb;11(2):133-139. doi: 10.2217/bmm-2016-0240. Epub 2017 Jan 18. Biomark Med. 2017. PMID: 28097894
-
YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease.Scand Cardiovasc J. 2008 Oct;42(5):295-302. doi: 10.1080/14017430802220567. Scand Cardiovasc J. 2008. PMID: 18615353
Cited by
-
Serum YKL-40 in coronary heart disease: linkage with inflammatory cytokines, artery stenosis, and optimal cut-off value for estimating major adverse cardiovascular events.Front Cardiovasc Med. 2023 Oct 31;10:1242339. doi: 10.3389/fcvm.2023.1242339. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 38028459 Free PMC article.
-
The benefit of exercise rehabilitation guided by 6-minute walk test on lipoprotein-associated phospholipase A2 in patients with coronary heart disease undergoing percutaneous coronary intervention: a prospective randomized controlled study.BMC Cardiovasc Disord. 2022 Apr 17;22(1):177. doi: 10.1186/s12872-021-02430-7. BMC Cardiovasc Disord. 2022. PMID: 35430800 Free PMC article. Clinical Trial.
-
Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40.PLoS One. 2018 Aug 23;13(8):e0202797. doi: 10.1371/journal.pone.0202797. eCollection 2018. PLoS One. 2018. PMID: 30138439 Free PMC article.
References
-
- Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104:2746–2753. - PubMed
-
- Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340:115–126. - PubMed
-
- Biasillo G, Leo M, Della BR, Biasucci LM. Inflammatory biomarkers and coronary heart disease: from bench to bedside and back. Intern Emerg Med 2010; 5:225–233. - PubMed
-
- Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006; 53:172–209. - PubMed
-
- Boot RG, van Achterberg TA, van Aken BE, Renkema GH, Jacobs MJ, Aerts JM, de Vries CJ. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol 1999; 19:687–694. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous